Bradley Scott Perrin

Bradley Scott Perrin

Auto-generated profile, based on publicly available information

Bradley Scott Perrin

Pfizer, Inc

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2022 in mBio
Verified
Journal Article
Open access
JLJonathan T. Lee
Jonathan T. Lee
QYQingyi Yang
Qingyi Yang
AGAlexey Gribenko
Alexey Gribenko
BPB. Scott Perrin
B. Scott Perrin
YZYuao Zhu
Yuao Zhu
LHLi Hao
Li Hao
The recent authorization of oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals, such as Paxlovid, has ushered in a new era of the COVID-19 pandemic. The emergence of new variants, as well as the selective pressure imposed by antiviral drugs themselves, raises concern for potential escape mutations in key drug binding motifs.

21 June 2022 in Research Square
Verified
Preprint
Open access
PDF file
HSHolly Soares
Holly Soares
MBMary Lynn Baniecki
Mary Lynn Baniecki
RCRhonda Cardin
Rhonda Cardin
HLHeidi Leister-Tebbe
Heidi Leister-Tebbe
YZYuao Zhu
Yuao Zhu
AAAnnaliesa Anderson
Annaliesa Anderson
Nirmatrelvir-ritonavir was developed for the treatment of COVID-19 and has shown efficacy in a Phase 2/3 study of high risk patients (EPIC-HR1). Monitoring for the emergence of viral resistance and recurrence of symptoms is a critical component of any antiviral drug development. As part of the study of viral resistance, a sub-analysis was conducted to examine viral load rebound (VLR) following nirmatrelvir-ritonavir treatment in the EPIC-HR study. Nasopharyngeal or nasal swabs were collected from all study participants at Day 1, Day 3, Day 5, Day 10, and Day 14, and analyzed for viral RNA load and next generation viral sequencing. Two categories of viral load rebound were considered including present/persistent and transient. In EPIC-HR, the proportion of present/persistent VLR was low, occurring at 1.73% (17/980) vs 2.32% (23/990) and for transient VLR 2.35% (23/980) vs 4.65% (46/990) in placebo vs nirmatrelvir-ritonavir participants, respectively. VLR occurred in both treatment arms and was not associated with low nirmatrelvir exposure, hospitalization or death, severe symptom relapse, serological status, or Mpro gene/cleavage treatment emergent mutations. In summary, viral load rebounds are likely a phenomena COVID-19 disease course and nirmatrelvir-ritonavir continue to be an important treatment option for high risk COVID-19 patients.

17 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
CCChiril Calin
Chiril Calin
DNDac-Trung Nguyen
Dac-Trung Nguyen
BPBradley Scott Perrin
Bradley Scott Perrin
The accurate prediction of b-cell epitopes facilitates vaccine development by identifying known antibodies for an antigen. Multiple epitope prediction models use protein language models to enable more accurate predictions with modest results. Here, we present EpiTune, a b-cell epitope prediction model that fine-tunes the underlying protein language model to deliver best-in-class predictions of linear epitopes and competitive predictions for confirmational epitopes. EpiTune achieves this performance from antigen sequence alone, and utilizes ESM-2's RoPE architecture to fine-tune and infer on sequences longer than other sequence-based models currently available in the literature. EpiTune's single-model architecture allows the model to determine the meaningfulness of sequence features for epitope prediction. This avoids the need for assigning importance to intermediates such as structure-based information, while still allowing a high degree of model interpretability.